PerkinElmer Buys BioLegend for $5.25 Billion in Cash, Stock
- BioLegend makes research tools for Covid-19, other diseases
- Largest purchase ever for PerkinElmer, companies say
This article is for subscribers only.
PerkinElmer Inc. agreed to buy BioLegend, a privately held maker of biomedical research tools for Covid-19 and other illnesses, for about $5.25 billion in shares and cash.
The acquisition, the largest-ever for Waltham, Massachusetts-based PerkinElmer, is expected to close by the end of this year, subject to regulatory approvals, the companies said in a statement Monday.